Cure8 research brief
Why This Matters
If reliable, an earlier day‑3 PUCAI cutoff could help identify children with flare‑related ASUC who are unlikely to respond to IV steroids and who may benefit from earlier planning for second‑line therapy rather than waiting to day 5.
Who Should Pay Attention
Pediatric gastroenterologists, inpatient clinicians, and parents/caregivers of children hospitalized with acute severe ulcerative colitis (especially flare‑related ASUC).
Study Snapshot
What To Know
This study included 91 biologic‑naïve children hospitalized with ASUC; about half required second‑line therapy.
For children whose ASUC occurred during a disease flare, a day‑3 PUCAI ≥50 showed high specificity (94.1%) and reasonable sensitivity (75%) for predicting steroid non‑response, and these patients had lower colectomy‑free rates and lower chance of clinical remission.
The authors conclude that in flare‑ASUC, a PUCAI ≥50 on day 3 could support earlier risk stratification and preparation for potential second‑line rescue therapy rather than waiting until day 5 per current guidelines.
Keep In Mind
Retrospective design and limited sample size mean results are hypothesis‑generating; this does not prove that earlier escalation improves outcomes. The extraction is from the article abstract.
Source Details
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest All authors declare no conflict of interest.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.